Dr. Jubin Osei-Mensah, Vera Serwaa Opoku, Francis Adjei Osei, Dr. Mrs. Linda Batsa Debrah, Prof. Alexander Yaw Debrah, Ruth Boateng, Eglah Agyeiwaa Appiah, Aliu Mohammed, Seth Wiredu, Paul Antwi, Nancy Ackam, Abu Abudu Rahamani, Eunice Kuutiero, Derrick Adu Mensah, Fatima Amponsah Fordjour, Ernest Amanor, Peter Akosah Gyamfi and Wellington Owusu.


Group leader: Prof. Richard O. Phillips

Phone: +233 209140451
E-Mail:  phillips@kccr.de

Post Doc, Team Leader: Dr. Michael Frimpong

Doctoral Students

Dr. Justice Boakye-Appiah
Mr Aloysius Loglo
Bernadette Agbavor
Nancy Ackam
Jonathan Agyei

Hubert S. Ahor

Research Assistance

Abigail Agbanyo
Michael O. Ntiamoah

Technical Staff (field):

Abass M. Kabiru (Agogo),
Elizabeth Ofori (Tepa),
George Amofa (Dunkwa)
Wilson Tuah (Nkawie)

Clinical Scientists:

Dr. Yaw A Amoako, MBChB, FWACP, FGCP
Dr. Solomon Gyabaah, MBChB,

Master/Bachelor Students:

Rejoice Arthur
Venus N. B. Frimpong
Wilfred Aniagyei
Louis Kyei- Tuffuor


Several West African countries are badly affected by Buruli ulcer, an unsightly skin condition caused by infection with Mycobacterium ulcerans. Buruli ulcer affects predominantly the upper and lower limbs of patients and common in rural tropical communities in West and Central Africa. In Ghana it is one of the commonest skin NTDs.

The Buruli ulcer group is particularly interested in promoting approaches aimed at early detection of the disease, understanding the mechanisms underlying disease pathogenesis, improving diagnostic confirmation and optimization of antibiotic treatment and its outcomes.

The group currently collaborates extensively with local partners and international partners from all over the world including Africa, United Kingdom, USA, Europe in carrying out research aimed at improving the care of Buruli ulcer patients globally. Our activities include training, planning, supervision, implementation of clinical and epidemiological studies.

Research Projects

Ongoing Research projects:

Evaluation of a nitric oxide generating dressing (EDX110) to improve management of Buruli ulcer disease

Treatment of Buruli ulcer disease caused by Mycobacterium ulcerans with antibiotics, rifampicin with clarithromycin given daily for 8 weeks has transformed the management of the disease. However, the rate of healing is highly variable even in patients with seemingly similar lesions. Preliminary evidence from studies in Ghana suggest that factors contributing to variability in healing rate include the initial bacterial load and/or development of paradoxical reactions. One approach to solving this problem would be to enhance killing of M. ulcerans. The antibiotics used as first line therapy were chosen for their bactericidal potency in a mouse model of M. ulcerans infection and it is unlikely that these can be improved upon particularly given the increasing global threat of antimicrobial resistance. We therefore propose an alternative approach, using concurrent treatment with a novel Nitric oxide-generating wound dressing and the antibiotics to enhance healing.

The primary objective is:

  • To compare healing, as measured by percentage area reduction, of EDX110 dressing with oral rifampicin and clarithromycin versus ‘Usual Care’ with routine Vaseline gauze dressing and oral rifampicin and clarithromycin.

Secondary objectives include:

  • A comparison of the number of complete healers and the recurrence rate in EDX 110 dressing and Vaseline gauze dressing groups.
  • A comparison of rate of killing of ulcerans in EDX 110 dressing and Vaseline gauze dressing groups.
  • Effect of treatment on the immune profiles of stimulated blood cells for biomarkers of healing
  • A comparison of the tolerability of the two dressings.
  • Training/ Mentoring of a cadre of Junior Scientists (PhD/Master students/Post doc/Clinical scientists)
  • Training of village volunteers in the use and application of the dressing materials

Study design

The study has been designed as a prospective randomized open-blinded end-point (PROBE) study of either rifampicin 10mg/kg and clarithromycin 15mg/kg daily AND Nitric oxide-generating gel dressing (EDX 110) applied on alternate days to the wound or rifampicin 10mg/kg and clarithromycin 15mg/kg daily AND Vaseline gauze dressings applied daily to the wound representing current standard of care. This will be conducted at the KCCR, Ghana and Agogo Presbyterian Hospital, Tepa and Dunkwa Government Hospitals all in Ghana.

Expected Impact

If treatment with topical Nitric oxide combined with oral antibiotics causes more rapid killing of M. ulcerans and enhances healing, treatment will be shortened and made more convenient for patients. This will improve the delivery of treatment. The study will likely produce high impact scientific papers. There will be a significant impact on the pool of trained junior scientists.

The trial has been registered with the Pan African Clinical Trial Registry with identification number PACTR201812819039144. (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5795) (www.pactr.org).

“This project is part of the EDCTP2 programme supported by the European Union”.



 It is cofunded by Edixomed Limited, UK, which provided the Nitric oxide dressings free of charge.

Laboratory support for the control and elimination of skin NTDs (Buruli ulcer, yaws and leprosy) in Ghana.

Summary of Project Aims: To provide laboratory diagnostic confirmation of Buruli ulcer, Yaws and Leprosy suspected cases to the ANESVAD supported project to the Ghana Health Service aimed at fighting these CM-NTDs in 15 selected districts.

Progress so far: Harmonization workshop with two other reference laboratory, Noguchi Memorial Institute for Medical Research and the Department of Chemistry, University of Ghana has been held to develop a standardized laboratory manual for the project. Our group is also providing diagnostic support to 7 districts that are part of the ANESVAD support program to the Ghana Health Service. We have also engaged in a number of training and monitory activities in these districts to enhance active case search of community health workers and volunteers.

Expected Outcomes / Impact: Improve laboratory diagnosis of BU/yaws/leprosy through strengthening of national and selected district laboratories. Train a cohort of laboratory technicians and health workers to support activities of the National NTD program.

The role of coagulation in the pathogenesis of Buruli ulcer

The necrotic subcutaneous tissue of the Buruli lesions can be extensive. Wound healing is a major issue in Buruli ulcer and healing rates can range widely between patients, although it is not clear why. Haemostatic components including thrombomodulin have known roles in wound healing, therefore this research will throw light onto these under-explored areas. This is a collaborative study with the University of Surrey (UK) and sponsored by a Wellcome Trust grant to Dr Rachel Simmonds. The overarching hypothesis is that disordered haemostasis in the skin tissue of BU patients initiates lesion formation and determines clinical susceptibility.  Here we at explore that role of haemostasis (blood clotting) in the pathogenesis of Buruli ulcer.

This study will substantially increase our understanding of the pathogenic mechanism of Buruli ulcer lesion development. It will show whether it might be possible to improve BU treatment strategies by harnessing anticoagulants alongside antibiotics to reduce healing times. It will contribute to knowledge of the interaction between coagulation and infectious diseases more widely.

Pathogenesis and management of M. ulcerans disease, Buruli ulcer  

This study sponsored by the MRC/DFID African Research Leader scheme aims to identify markers of rapid response to antibiotic treatment in Mycobacterium ulcerans disease and to investigate the pathogenesis of oedematous disease and paradoxical reactions in M. ulcerans disease. Methods include molecular, mass spectrometry and immunological approaches using flow cytometry. Proteome biomarkers are validated for field applicability.

Using a novel a novel molecular assay we already show that patients with detectable viable organisms after antibiotic treatment had significantly higher bacterial load at baseline, longer healing time and lower healing rate at week 4 compared with those with undetectable viable organisms at baseline or by week 4.

Results suggest that although current antibiotic therapy for BU disease is highly successful in most patients it may be possible to abbreviate treatment to 4 weeks in patients with a low initial bacterial load. On the other hand persistent infection contributes to slow healing in patients with a high bacterial load, some of whom may need antibiotics for longer than 8 weeks. 1 PhD students and 4 MSc students have been trained on this project

Co-infection of M. tuberculosis or M ulcerans with Mansonella perstans in Ghana and Cameroun

The DFG provided sponsorship for our group and partners in the University of Bonn and Duesseldorf ( Germany) and University of Buea (Cameroon) to better understand the effect of Mansonella perstans co-infection on mycobacterial diseases such as Buruli ulcer and Tuberculosis.

M. perstans is one of the most prevalent human parasites in sub-Saharan Africa. However the epidemiology of M. perstans in most regions and relevant transmitting vector species are poorly defined. We were able to characterize ecological zones prerequisite for M. perstans infection and identified a potential novel vector for transmission of M. perstans in the initial project period. Amongst others we demonstrated that M. perstans infections are strongly linked to dense equatorial rainforest areas and mass drug administration with the anti-helminthic drug ivermectin had limited efficacy on M. perstans prevalence in areas with optimal vector habitat (Wanji el al. Parasit Vectors, 2016). In addition, we could show that Culicoides (C.) milnei is the transmitting vector for M. perstans in South-West region within Cameroon

Mansonella perstans (M. perstans) epidemiology, the role of Wolbachia endosymbionts and M. perstans infection effects on host immunity. In addition we characterized immunological mechanisms crucial for protection as well as pathognomonic features of mycobacterial diseases (i.e. Buruli disease and tuberculosis). Outstanding progress has been made in several topics and great collaborations have been established between the partner institutes from Ghana, Cameroon, and Germany. These achievements enable us now to target challenging efficacy trials on the role of M. perstans for M. bovis BCG vaccine induced protection as well as tuberculosis disease manifestation and recovery in Ghana and Cameroon.

Title: A randomised controlled trial to evaluate the effect of High Dose Rifampicin and Dialkylcarbamoyl chloride (DACC)-coated dressings on outcomes in Mycobacterium ulcerans disease

The current recommended regimen for the treatment of Buruli ulcer disease is oral rifampicin (10mg/kg dose) together with oral clarithromycin or intramuscular streptomycin for 8 weeks and giving the increasing global threat of antimicrobial resistance. Despite antibiotic treatment, wound healing remains prolonged in BU. Preliminary evidence from studies in Ghana indicates two main factors contributing to variability in healing rate, i) the bacterial load at baseline and ii) the development of paradoxical reactions, with renewed inflammation, despite progressive bacterial killing by antibiotics. Previous studies have demonstrated either healing or lack of detectable live MU in 46% of patients by week 4 of treatment, suggesting that a shorter course of antibiotics may suffice for some patients, whereas, in those with unhealed lesions at week 8, more than 50% had detectable live organisms using the combined 16S rRNA assay and qPCR for IS2404.

An additional factor that needs consideration is the possible role of secondary infections of BU wounds. Data suggest that combining high-dose Rifampicin (HDR) and DACC dressings may significantly improve the time to clearance of viable mycobacterium from wounds, reduce the risk of paradoxical reactions and secondary infections, reduce the time for treatment and therefore improve outcomes for patients with BU. Our aim is to reduce this regimen and minimize the antibiotic treatment period by determining the efficacy of combining oral high-dose Rifampicin and topical DACC dressing to improve healing outcomes.

In addition, an economic evaluation will be conducted to assess the incremental costs and cost-effectiveness of switching from standard BU treatment strategies to either HR+DACC or SR+DACC using existing data from previous BU trials.

Aims and Objectives

The aim of the study is to determine the ability of high-dose oral Rifampicin (20mg/kg) and DACC dressings to improve the time to clearance of viable mycobacterium from Buruli ulcer wounds compared to a regime using standard dose oral Rifampicin (10mg/kg) and DACC dressings.

Primary objective

  • Compare the time to clearance of viable Mycobacterium from wounds of patients treated with high-dose Rifampicin and DACC dressings (HR+DACC) to those receiving standard dose Rifampicin and DACC dressings (SR+DACC).

 Secondary objectives

  • Assess impact of high-dose Rifampicin and DACC dressings on the proportion of wounds healed at 20 weeks
  • Assess the rate of paradoxical reactions between groups
  • Asses the recurrence rate in both groups
  • Use historic control data to compare the time to clearance of viable Mycobacterium in patients receiving standard dose Rifampicin and Vaseline gauze dressings.
  • Evaluate the incremental costs and cost-effectiveness of high dose Rifampicin vs standard dose Rifampicin

Expected Impact

Success in this project would have a major impact on the management of Buruli ulcer, with faster healing leading to shorter treatment duration for many patients. Further, economic and social benefits could be significant. Reducing the use of antibiotics to treat presumed secondary infections could result in significant cost savings to the healthcare system and additionally provide the opportunity for patients to receive more of their treatment at the community level.

Training Health Workers and to Implement Case Detection for SkinNTD in Ghana (THECA-DES)

Over the years, the WHO has proposed an integrated approach to NTD management as funding keeps dwindling. The cost of sustaining individual NTD programs is rising and the competition for securing funds is also getting keener. Currently, NTDs are underfunded with no ongoing active case search without sustainable capacity building efforts.

We aim to develop an operational research agenda to contribute to addressing gaps relating to control, elimination, and eradication of skin NTDs in the country. This will be solved by a set of activities:

Activity 1: Organize a workshop for health workers from the districts and other relevant facilities in disease hotspots to identify gaps in Skin-NTDs control, elimination, and eradication to help develop an operational research plan to address them.

Activity 2: Propose and implement innovative strategies to enhance and sustain case detection in selected districts to help understand the extent of under-reporting of cases.

We will train health workers and implement case detection for Skin-NTDs in seven districts in Ghana. The targeted districts are: Sekyere East District, Ahafo Ano North district, Asutifi (North & South) districts, Asunafo South District, Ga South, and Ga West Districts. The training aspect will include workshop for stakeholders to develop operational research agenda for Skin-NTDs. The skin-NTDs that will be of most interest include Yaws, Buruli ulcer, Leprosy and Scabies. CBSVs and health workers will be trained prior case search. We will implement three main innovative strategies which include testing the diagnostic accuracy of Buruli ulcer clinical scoring checklist, implementation of the DHIS2 platform and use of telecommunication technology to improve patient care.

Expected outcome/Impact

  • Evidence provided on the impact of active and passive case search on case identification
  • Profile of skin NTDs in these selected districts determined will provide insight into

   the endemicity of these diseases in these communities’ post COVID19

  • Evidence-based feedback on Skin NTDs will be provided especially on those that

   need attention in line with the WHO Road Map 2030

  • Impact of training on improved care for NTDs established
  • Maps will be generated from skin NTD endemic areas

This project is sponsored by the World Health Organization (WHO).

Scabies Treatment and Its Complications in Ghana.

Scabies is one of the commonest dermatological conditions worldwide estimated to affect over 200 million people at any time. However, evidence seems to suggest that this condition as one of the most under-reported or misdiagnosed skin diseases in the country and this is mostly due to limited expertise on the subject matter by most clinicians, raising a cause for concern.

The focus on this condition by the group is stemmed by the core mandate of the team to tackle skin neglected tropical diseases within the country. Due to the highly focal nature of the disease, outbreaks tend to be common and this can cause a lot of discomfort and cause some socio-economic burdens on affected individuals and their households.

The project is a collaborative effort between the KCCR team led by Prof. Richard O. Phillips and Dr. Yaw Amoako Ampem in Ghana and the University Medical Center for Groningen led by Prof. Dr. Ymkje Stienstra in the Netherlands. The Scabies team is focused on using questionnaire-based surveys and such similar approaches, to collect data on the disease burden and the knowledge, beliefs and attitudes to scabies within various households, schools and other entities in the communities targeted, in order to estimate diseases prevalence and inform for the implementation of interventions and policies which may be scaled up to regional and national levels. This is in line with the WHO action criteria 1 for scabies and other ectoparasites.

Works have by far been done at the East Mamprusi District in the Northern region of Ghana and currently at the Sekyere East district in the Ashanti region where outbreaks have been reported by health professionals based there. The team has also been in partnership with health personnel from the Kokofu health center for the study.

The team hopes to contribute substantial and accurate data on scabies to serve as the backdrop against which more focus may be invested into the control and management of scabies within the country. This may facilitate the use of interventions such as MDAs for the control of the disease.

Recently completed projects:

Mental Health in Buruli ulcer disease (BUMEN)

There is increasing evidence of the association between Neglected Tropical Diseases (NTDs) and mental health. Nevertheless, only a few NTDs have been robustly studied in this regard. Previous studies have assessed mental health in NTDs, such as leprosy, leishmaniasis, and lymphatic filariasis. There is a relative lack of data regarding the impact on mental health burden and Quality of Life (QOL) of persons affected by BUD. We assessed the impact of BUD on the mental health and QoL of BUD patients and caregivers. In this study, we further provide evidence to highlight that people affected by BUD have a significantly reduced QoL. We also show a significant mental distress in BUD is associated with physical and functional limitation in patients and bears psychological impact on caregivers as well. We highlight the need for community education and integration of psychosocial interventions in BUD management.

Training and field evaluation of new diagnostic tool for Buruli ulcer in Ghana

The goal of this work is to establish fluorescent thin layer chromatography in endemic sites and to train laboratory technicians from 6 Buruli ulcer endemic districts in Ghana on a standard protocol for this new diagnostic tool for Buruli ulcer disease and in its field evaluation.


Amoako YA, Ackam N, Omuojine JP, Oppong MN, Owusu-Ansah AG, Abass MK, Amofa G, Ofori E, Frimpong M, Bailey F, Molyneux DH, Phillips RO. Caregiver burden in Buruli ulcer disease: Evidence from Ghana. PLoS Negl Trop Dis. 2021 Jun
1;15(6):e0009454. doi: 10.1371/journal.pntd.0009454. PMID: 34061828; PMCID: PMC8195390.

Simpson H, Tabah EN, Phillips RO, Frimpong M, Maman I, Ampadu E, Timothy J, Saunderson P, Pullan RL, Cano J. Mapping suitability for Buruli ulcer at fine spatial scales across Africa: A modelling study. PLoS Negl Trop Dis. 2021 Mar
3;15(3):e0009157. doi: 10.1371/journal.pntd.0009157. PMID: 33657104; PMCID: PMC7959670.

Frimpong M, Kyei-Tuffuor L, Fondjo LA, Ahor HS, Adjei-Kusi P, Maiga-Ascofare O, Phillips RO. Evaluation of a real-time recombinase polymerase amplification assay for rapid detection of Schistosoma haematobium infection in resource-limited
setting. Acta Trop. 2021 Apr;216:105847. doi: 10.1016/j.actatropica.2021.105847. Epub 2021 Jan 23. PMID: 33497617.

Amoako YA, Phillips RO, Arthur J, Abugri MA, Akowuah E, Amoako KO, et al. (2020) A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention. PLoS Negl Trop Dis 14(12): e0008902. https://doi.org/10.1371/journal.pntd.0008902

Mabey D, Agler E, Amuasi JH, Hernandez L, Hollingsworth TD, Hotez PJ, Lammie PJ, Malecela MN, Matendechero SH, Ottesen E, Phillips RO, Reeder JC, Szwarcwald CL, Shott JP, Solomon AW, Steer A, Swaminathan S. Towards a comprehensive research
and development plan to support the control, elimination and eradication of neglected tropical diseases. Trans R Soc Trop Med Hyg. 2021 Jan 28;115(2):196-199. doi: 10.1093/trstmh/traa114. PMID: 33179054; PMCID: PMC7842110.

Van Der Werf TS, Barogui YT, Converse PJ, Phillips RO, Stienstra Y. Pharmacologic management of Mycobacterium ulcerans infection. Expert Rev Clin Pharmacol. 2020 Apr;13(4):391-401. doi: 10.1080/17512433.2020.1752663. Epub 2020 Apr 20. PMID: 32310683.

 Phillips RO, Robert J, Abass KM, Thompson W, Sarfo FS, Wilson T, Sarpong G, Gateau T, Chauty A, Omollo R, Ochieng Otieno M, Egondi TW, Ampadu EO, Agossadou D, Marion E, Ganlonon L, Wansbrough-Jones M, Grosset J, Macdonald JM, Treadwell T,
Saunderson P, Paintsil A, Lehman L, Frimpong M, Sarpong NF, Saizonou R, Tiendrebeogo A, Ohene SA, Stienstra Y, Asiedu KB, van der Werf TS; study team. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet. 2020 Apr 18;395(10232):1259-1267. doi: 10.1016/S0140-6736(20)30047-7. Epub 2020 Mar 12. PMID: 32171422; PMCID: PMC7181188.

Frimpong M, Simpson SV, Ahor HS, Agbanyo A, Gyabaah S, Agbavor B, Amanor IB, Addo KK, Böhlken-Fascher S, Kissenkötter J, Wahed AAE, Phillips RO. Multiplex Recombinase Polymerase Amplification Assay for Simultaneous Detection of Treponema
and Haemophilus ducreyi in Yaws-Like Lesions. Trop Med Infect Dis. 2020 Oct 6;5(4):157. doi: 10.3390/tropicalmed5040157. PMID: 33036234; PMCID: PMC7709673.

Collinson S, Frimpong VNB, Agbavor B, Montgomery B, Oppong M, Frimpong M, Amoako YA, Marks M, Phillips RO. Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana. PLoS Negl Trop Dis. 2020 May 26;14(5):e0008369. doi: 10.1371/journal.pntd.0008369. PMID: 32453800; PMCID: PMC7274448.

Neary M, Olagunju A, Sarfo F, Phillips R, Moss D, Owen A, Chadwick D. Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. Journal of Antimicrobial Chemotherapy. 2020 Feb 14.

Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L, Austin H, Awuah D, Beloukas A, Chadwick D, Phillips R. Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa. EClinicalMedicine. 2020 Jan 1;18:100231

Omansen TF, van der Werf TS, Phillips RO. Antimicrobial Treatment of Mycobacterium ulcerans Infection. 2019 Apr 30. In: Pluschke G, Röltgen K,editors. Buruli Ulcer: Mycobacterium Ulcerans Disease [Internet]. Cham (CH):Springer; 2019. Available from http://www.ncbi.nlm.nih.gov/books/NBK553822/ PubMed PMID: 32091697.

Di Cristanziano V, Weimer K, Böttcher S, Sarfo FS, Dompreh A, Cesar LG, Knops E, Heger E, Wirtz M, Kaiser R, Norman B, Phillips RO, Feldt T, Eberhardt KA. Molecular Characterization and Clinical Description of Non-Polio Enteroviruses Detected in Stool Samples from HIV-Positive and HIV-Negative Adults in Ghana. Viruses. 2020 Feb 16;12(2). pii: E221. doi: 10.3390/v12020221. PubMed PMID:32079128.

Phillips, R.O. (2019, December 31). Mycobacterium ulcerans disease: Buruli Ulcer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 7, 2020, from https://hstalks.com/bs/3962/.

Wadagni AC, Steinhorst J, Barogui YT, Catraye PM, Gnimavo R, Abass KM, Amofa G, Frimpong M, Sarpong FN, van der Werf TS, Phillips R. Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa. PLoS neglected tropical diseases. 2019 Oct;13(10).

Stienstra Y, Beeres DT, Phillips R, Vonk M, Ravensbergen SJ. The public health control of scabies: priorities for research and action. Lancet (London, England). 2019 Dec 7;394(10214):2068.

Frimpong M, Ahor HS, Sakyi SA, Agbavor B, Akowuah E, Phillips RO. Rapid Extraction Method of Mycobacterium ulcerans DNA from Clinical Samples of Suspected Buruli Ulcer Patients. Diagnostics. 2019 Dec;9(4):204.

Seyfarth J, Sarfo‐Kantanka O, Rosenbauer J, Phillps RO, Jacobsen M. Type‐1 diabetes onset age and sex differences between Ghanaian and German urban populations. Journal of diabetes. 2019 Dec;11(12):1002-1004. doi: 10.1111/1753-0407.12978

Richard Odame Phillips Buruli ulcer (Mycobacterium ulcerans disease) Henry Stewart online lectures Edited by Professor Molyneux of the Liverpool School of Tropical Medicine, UK Available at   https://hstalks.com/playlist/1063/neglected-tropical-diseases/ (accessed 4th October 2019)

Di Cristanziano V, D Alfonso R, Berrilli F, Sarfo FS, Santoro M, Fabeni L, Knops E, Heger E, Kaiser R, Dompreh A, Phillips RO, Norman B, Feldt T, Eberhardt KA. Lower prevalence of Blastocystis sp. infections in HIV positive compared to HIV negative adults in Ghana. PLoS One. 2019 Sep 3;14(9):e0221968. doi: 10.1371/journal.pone.0221968. Erratum in: PLoS One. 2019 Oct 11;14(10):e0224000.

Frimpong M, Agbavor B, Duah MS, Loglo A, Sarpong FN, Boakye-Appiah J, Abass KM, Dongyele M, Amofa G, Tuah W, Frempong M, Amoako YA, Wansbrough-Jones M, Phillips RO. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load. PLoS Negl Trop Dis. 2019 Aug;13(8):e0007689.

Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, Ampadu E, Phillips R, Saunderson P, Pullan RL, Cano J. Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus. Lancet Glob Health.2019 Jul;7(7):e912-e922.

Adankwah E, Güler A, Mayatepek E, Phillips RO, Nausch N, Jacobsen M. CD27 expression of T-cells discriminates IGRA-negative TB patients from healthy contacts in Ghana. Microbes Infect. 2019 Aug 12;. doi: 10.1016/j.micinf.2019.07.003

Amoako YA, Frimpong M, Awuah DO, Plange-Rhule G, Boakye-Yiadom E, Agbavor B, Sarpong F, Ahor H, Adu E, Danso KG, Abass MK, Asiedu K, Wansbrough-Jones M, Phillips RO. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports. J Med Case Rep. 2019 Jul 18;13(1):218.

Adankwah E, Lundtoft C, Güler A, Franken KLMC, Ottenhoff THM, Mayatepek E, Owusu-Dabo E, Phillips RO, Nausch N, Jacobsen M. Two-Hit in vitro T-Cell Stimulation Detects Mycobacterium tuberculosis Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana. Front Immunol. 2019 Jul 3;10:1518. doi: 10.3389/fimmu.2019.01518.

Batsa Debrah L, Phillips RO, Pfarr K, Klarmann-Schulz U, Opoku VS, Nausch N, Owusu W, Mubarik Y, Sander AL, Lämmer C, Ritter M, Layland LE, Jacobsen M, Debrah AY, Hoerauf A. The Efficacy of Doxycycline Treatment on Mansonella perstans Infection: An Open-Label, Randomized Trial in Ghana. Am J Trop Med Hyg. 2019 Jul;101(1):84-92.

Awua-Boateng NY, Mohammed A, Aglanu LM, Acheampong G, Amuasi JH, Bonsu FA, Phillips RO, Owusu-Dabo E. Is pulmonary tuberculosis in pregnant women a problem in Ghana? Observations and lessons from the national tuberculosis prevalence project. Int J Mycobacteriol. 2019 Jul-Sep;8(3):267-272.

Beeres DT, Horstman J, van der Tak P, Phillips RO, Abass KM, van der Werf T, Johnson RC, Sopoh GE, de Zeeuw J, Dijkstra PU, Barogui YT, Stienstra Y. The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. PLoS Negl Trop Dis. 2019 Mar;13(3):e0007273.

Frimpong M, Ahor HS, Wahed AAE, Agbavor B, Sarpong FN, Laing K, Wansbrough-Jones M, Phillips RO. Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay. PLoS Negl Trop Dis. 2019 Feb;13(2):e0007155.

Villa G, Phillips RO, Smith C, Stockdale AJ, Ruggiero A, Beloukas A, Appiah LT, Chadwick D, Sarfo FS, Geretti AM. Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring. J Antimicrob Chemother. 2018 Nov 1;73(11):3148-3157.

Lundtoft C, Awuah AA, Güler A, Harling K, Schaal H, Mayatepek E, Phillips RO, Nausch N, Owusu-Dabo E, Jacobsen M. An IL7RA exon 5 polymorphism is associated with impaired IL-7Rα splicing and protection against tuberculosis in Ghana. Genes Immun. 2018 Oct 31

Phillips RO, Steinmetz A, Nichols J, Adomako E, Ofori E, Antonio E, Allihien SM, Peprah-Addae C, Adams W. Spectrum of disease in HIV-positive patients presenting to a tertiary care hospital: a retrospective, cross-sectional review in Kumasi, Ghana. BMC Infect Dis. 2018 Aug 23;18(1):419.

Loglo AD, Frimpong M, Sarpong Duah M, Sarfo F, Sarpong FN, Agbavor B, Boakye-Appiah JK, Abass KM, Dongyele M, Frempong M, Pidot S, Wansbrough-Jones M, Stinear TP, Roupie V, Huygen K, Phillips RO. IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection. PeerJ. 2018 Jul 31;6:e5294. doi: 10.7717/peerj.5294

Marks, M., Mitjà, O., Bottomley, C., Kwakye, C., Houinei, W., Bauri, M., Adwere, P., Abdulai, A.A.,Dua, F., Boateng, L., Wangi, J., Ohene, S.-A., Wangnapi, R., Simpson, S.V., Miag, H., Addo, K.K.,Basing, L.A., Danavall, D., Chi, K.H., Pillay, A., Ballard, R., Solomon, A.W., Chen, C.Y., Bieb, S.V.,Adu-Sarkodie, Y., Mabey, D.C.W., Asiedu, K., Hounei, W., Agana, N., Ampadu, E.,Amponsah-Achiano, K., Bediako, A., Biredu, M., Faried, K., Iddrisu, A., Kotey, N.K., Yeboah, G.N.,El-Duah, P., Phillips, R., Binka, F., Nyonator, F., Zunuo, A., Ackumey, M.A., Amanor, I., Bnosu, C.,Frischmann, S., Lammie, P., Martin, D., Ye, T., Christophel, E., Tiendrebeogo, A., Vestergard, L.,Bassat, Q., Abdad, Y., Dima, H., Kotty, B., Mamore, K., Manup, W., Olowau, B., Agyei, E.O.,Agyemang, D., Ako, E.P., Antwi, P., Darko, J., Darko, O.O., Darko, P., Duodu, B., Jabasi, D., Karim,F.L., Koomson, O.K., Labri, B.A., Nartey, J., Tamatey, R., Yirenkyi, B., Arhin, M., Biney, F., Danso,J.O., Dei, M.A., Djan, M., Sasu, S., Solomon, B.A., Torvinya, V., Amankwaah, H., Baffoe, J., Keteku,L., Kondobala, K., Lomotey, R.D., Nartey, A.A., Oppong, P., Quainoo, M.A., Abotsi, T., Agebshie, D.,Ameamu, A., Angwaawie, P., Ayibor, R., Mwingmendeli, M., Nakodia, J.,Nambagyira, A., Nanga, D.,Tetteh, N., Wanaom, A. Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea. Lancet Glob Health. 2018 Apr;6(4):e401-e410.

Villa G, Phillips RO, Smith C, Stockdale AJ, Beloukas A, Appiah LT, Chadwick D, Ruggiero A, Sarfo FS, Post F, Geretti AM. Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana. J Infect. 2018 Jun;76(6):515-521

Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, Phillips R, Asiedu K. Buruli Ulcer: a Review of the Current Knowledge. Curr Trop Med Rep. 2018;5(4):247-256. doi: 10.1007/s40475-018-0166-2. Epub 2018 Sep 28.

Geretti AM, King S, Adjei-Asante K, Appiah LT, Owusu DO, Sarfo FS, Chadwick D, Phillips RO, Beloukas A. Hepatitis C Virus (HCV) RNA screening and sequencing using dry plasma spots. J Clin Virol. 2017 Dec;97:18-21.

Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A, King S, Bonnett L, Geretti AM. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017 Oct;5(10):e992-e1003..

Chan HLY, Chen CJ, Omede O, Al Qamish J, Al Naamani K, Bane A, Tan SS, Simonova M, Cardenas I, Derbala M, Akin O, Phillips RO, Abdelmageed MK, Abdulla M, Adda D, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mateva L, Mitova R, Mohamed R, Morović M, Murphy K, Mustapha B, Nersesov A, Ngige E, Njouom R, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omuemu C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Su TH, Sultan K, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Nde H. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm: Volume 4. J Viral Hepat. 2017 Oct;24 Suppl 2:25-43.

Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat. 2017 Oct;24 Suppl 2:8-24.

Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, Garcia V, Rios C, Mateva L, Njoya O, Al-Busafi SA, Abdelmageed MK, Abdulla M, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mitova R, Mohamed R, Morović M, Murphy K, Nde H, Ngige E, Njouom R, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Rinke de Wit T, Robbins S, Roberts LR, Sanad SJ, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Schmelzer JD. Strategies to manage hepatitis C virus infection disease burden-Volume 4. J Viral Hepat. 2017 Oct;24 Suppl 2:44-63.

Sarpong-Duah M, Frimpong M, Beissner M, Saar M, Laing K, Sarpong F, Loglo AD, Abass KM, Frempong M, Sarfo FS, Bretzel G, Wansbrough-Jones M, Phillips RO. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay. PLoS Negl Trop Dis. 2017 Jul;11(7):e0005695.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176.

Nausch N, Antwi-Berko D, Mubarik Y, Abass KM, Owusu W, Owusu-Dabo E, Debrah LB, Debrah AY, Jacobsen M, Phillips RO. Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression. PLoS Negl Trop Dis. 2017 Feb;11(2):e0005415.

Debrah LB, Nausch N, Opoku VS, Owusu W, Mubarik Y, Berko DA, Wanji S, Layland LE, Hoerauf A, Jacobsen M, Debrah AY, Phillips RO. Epidemiology of Mansonella perstans in the middle belt of Ghana. Parasit Vectors. 2017 Jan 7;10(1):15.

Richard Phillips, Fred Sarfo, Mabel Sarpong Duah, Mark Wansbrough Jones, Michael Frimpong: Buruli ulcer: wound care and rehabilitation. Chronic Wound Care Management and Research 2016; December Volume 3(Issue 1) pages 73-84 .

Velink A, Woolley RJ, Phillips RO, Abass KM, van der Werf TS, Agumah E, de Zeeuw J, Klis S, Stienstra Y. Former Buruli Ulcer Patients’ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. PLoS Negl Trop Dis. 2016 Dec;10(12):e0005261.

Woolley RJ, Velink A, Phillips RO, Thompson WA, Abass KM, van der Werf TS, de Zeeuw J, Stienstra Y. Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients. Am J Trop Med Hyg. 2016 Nov 2;95(5):1011-1015.

Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016 Jan;18(1):17-29.

Barogui YT, Klis SA, Johnson RC, Phillips RO, van der Veer E, van Diemen C, van der Werf TS, Stienstra Y. Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer. PLoS Negl Trop Dis. 2016 Apr;10(4):e0004594.

Stockdale AJ, Phillips RO, Geretti AM. The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: ‘The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa’ by Lemoine et al. Gut. 2016 May;65(5):882-4. 

Ofori A, Steinmetz AR, Akaasi J, Asafu Adjaye Frimpong GA, Norman BR, Obeng-Baah J, Bedu-Addo G, Phillips RO. Pulmonary aspergilloma: An evasive disease. Int J Mycobacteriol. 2016 Jun;5(2):235-9.

Boakye-Appiah JK, Steinmetz AR, Pupulampu P, Ofori-Yirenkyi S, Tetteh I, Frimpong M, Oppong P, Opare-Sem O, Norman BR, Stienstra Y, van der Werf TS, Wansbrough-Jones M, Bonsu F, Obeng-Baah J, Phillips RO. High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. Int J Mycobacteriol. 2016 Jun;5(2):226-30.

Stockdale AJ, Phillips RO, Beloukas A, Appiah LT, Chadwick D, Bhagani S, Bonnett L, Sarfo FS, Dusheiko G, Geretti AM. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Clin Infect Dis. 2015 Sep 15;61(6):883-91.

de Zeeuw J, Alferink M, Barogui YT, Sopoh G, Phillips RO, van der Werf TS, Loth S, Molenbuur B, Plantinga M, Ranchor AV, Stienstra Y. Assessment and Treatment of Pain during Treatment of Buruli Ulcer. PLoS Negl Trop Dis. 2015;9(9):e0004076.

Beissner M, Phillips RO, Battke F, Bauer M, Badziklou K, Sarfo FS, Maman I, Rhomberg A, Piten E, Frimpong M, Huber KL, Symank D, Jansson M, Wiedemann FX, Banla Kere A, Herbinger KH, Löscher T, Bretzel G. Loop-Mediated Isothermal Amplification for Laboratory Confirmation of Buruli Ulcer Disease-Towards a Point-of-Care Test. PLoS Negl Trop Dis. 2015 Nov;9(11):e0004219.

Eberhardt KA, Sarfo FS, Dompreh A, Kuffour EO, Geldmacher C, Soltau M, Schachscheider M, Drexler JF, Eis-Hübinger AM, Häussinger D, Bedu-Addo G, Phillips RO, Norman B, Burchard GD, Feldt T. Helicobacter pylori Coinfection Is Associated With Decreased Markers of Immune Activation in ART-Naive HIV-Positive and in HIV-Negative Individuals in Ghana. Clin Infect Dis. 2015 Nov 15;61(10):1615-23.

Wadagni A, Frimpong M, Phanzu DM, Ablordey A, Kacou E, Gbedevi M, Marion E, Xing Y, Babu VS, Phillips RO, Wansbrough-Jones M, Kishi Y, Asiedu K. Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography. PLoS Negl Trop Dis. 2015 Nov;9(11):e0004247.

Sarfo FS, Eberhardt KA, Dompreh A, Kuffour EO, Soltau M, Schachscheider M, Drexler JF, Eis-Hübinger AM, Häussinger D, Oteng-Seifah EE, Bedu-Addo G, Phillips RO, Norman B, Burchard G, Feldt T. Helicobacter pylori Infection Is Associated with Higher CD4 T Cell Counts and Lower HIV-1 Viral Loads in ART-Naïve HIV-Positive Patients in Ghana. PLoS One. 2015;10(11):e0143388.

Chadwick DR, Sarfo FS, Kirk ES, Owusu D, Bedu-Addo G, Parris V, Owusu AL, Phillips R. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol. 2015 Dec 1;16:195..

Niang F, Sarfo FS, Frimpong M, Guenin-Macé L, Wansbrough-Jones M, Stinear T, Phillips RO, Demangel C. Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease. Sci Rep. 2015 Dec 4;5:17693.

Forbi JC, Layden JE, Phillips RO, Mora N, Xia GL, Campo DS, Purdy MA, Dimitrova ZE, Owusu DO, Punkova LT, Skums P, Owusu-Ofori S, Sarfo FS, Vaughan G, Roh H, Opare-Sem OK, Cooper RS, Khudyakov YE. Next-Generation Sequencing Reveals Frequent Opportunities for Exposure to Hepatitis C Virus in Ghana. PLoS One. 2015;10(12):e0145530.

Alferink M, de Zeeuw J, Sopoh G, Agossadou C, Abass KM, Phillips RO, Loth S, Jutten E, Barogui YT, Stewart RE, van der Werf TS, Stienstra Y, Ranchor AV. Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin. PLoS One. 2015;10(6):e0119926.

Purdy MA, Forbi JC, Sue A, Layden JE, Switzer WM, Opare-Sem OK, Phillips RO, Khudyakov YE. A re-evaluation of the origin of hepatitis C virus genotype 2 in West Africa. J Gen Virol. 2015 Aug;96(8):2157-64.

King S, Adjei-Asante K, Appiah L, Adinku D, Beloukas A, Atkins M, Sarfo SF, Chadwick D, Phillips RO, Geretti AM. Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana. J Viral Hepat. 2015 May;22(5):461-8.

Layden JE, Phillips RO, Owusu-Ofori S, Sarfo FS, Kliethermes S, Mora N, Owusu D, Nelson K, Opare-Sem O, Dugas L, Luke A, Shoham D, Forbi JC, Khudyakov YE, Cooper RS. High frequency of active HCV infection among seropositive cases in west Africa and evidence for multiple transmission pathways. Clin Infect Dis. 2015 Apr 1;60(7):1033-41.

Phillips RO, Phanzu DM, Beissner M, Badziklou K, Luzolo EK, Sarfo FS, Halatoko WA, Amoako Y, Frimpong M, Kabiru AM, Piten E, Maman I, Bidjada B, Koba A, Awoussi KS, Kobara B, Nitschke J, Wiedemann FX, Kere AB, Adjei O, Löscher T, Fleischer B, Bretzel G, Herbinger KH. Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis. 2015 Jan;9(1):e3457.

Abass KM, van der Werf TS, Phillips RO, Sarfo FS, Abotsi J, Mireku SO, Thompson WN, Asiedu K, Stienstra Y, Klis SA. Buruli ulcer control in a highly endemic district in Ghana: role of community-based surveillance volunteers. Am J Trop Med Hyg. 2015 Jan;92(1):115-7.

Frimpong M, Sarpong-Duah M, Beissner M, Sarfo, FS,, Loglo AD, Tannor E, Awuah NY1, Frempong M, Adjei O, Wansbrough-JonesM, Bretzel G, Phillips RO Microscopy for Acid Fast Bacilli: A Useful but Neglected Tool in RoutineLaboratory Diagnosis of Buruli Ulcer. J Trop Dis 2015, 3: 158.

de Zeeuw J, Omansen TF, Douwstra M, Barogui YT, Agossadou C, Sopoh GE, Phillips RO, Johnson C, Abass KM, Saunderson P, Dijkstra PU, van der Werf TS, Stienstra Y. Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin. PLoS Negl Trop Dis. 2014 Nov;8(11):e3303.

de Zeeuw J, Douwstra M, Omansen TF, Sopoh GE, Johnson C, Phillips RO, Alferink M, Saunderson P, Van der Werf TS, Dijkstra PU, Stienstra Y. Psychometric properties of the participation scale among former buruli ulcer patients in Ghana and Benin. PLoS Negl Trop Dis. 2014;8(11):e3254.

Sarfo FS, Kasim A, Phillips R, Geretti AM, Chadwick DR. Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana. J Infect. 2014 Nov;69(5):481-9.

Sarfo FS, Sarfo MA, Norman B, Phillips R, Bedu-Addo G, Chadwick D. Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy. PLoS One. 2014;9(10):e111400.

Phillips RO, Sarfo FS, Abass MK, Frimpong M, Ampadu E, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M. Reply to “compliance with antimicrobial therapy for buruli ulcer". Antimicrob Agents Chemother. 2014 Oct;58(10):6341. doi: 10.1128/AAC.03874-14. PubMed PMID: 25225343; PubMed Central PMCID: PMC4187934.

Layden JE, Phillips R, Opare-Sem O, Akere A, Salako BL, Nelson K, Dugas L, Luke A, Tayo BO, Cooper RS. Hepatitis C in sub-saharan Africa: urgent need for attention. Open Forum Infect Dis. 2014 Sep;1(2):ofu065

Geroult S, Phillips RO, Demangel C. Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings. J Wound Care. 2014 Aug;23(8):417-8, 422-4.

Klis S, Ranchor A, Phillips RO, Abass KM, Tuah W, Loth S, Velding K, van der Werf TS, Stienstra Y. Good quality of life in former Buruli ulcer patients with small lesions: long-term follow-up of the BURULICO trial. PLoS Negl Trop Dis. 2014 Jul;8(7):e2964.

Sarfo FS, Thompson W, Phillips RO, Paintsil A, Abass MK, Frimpong M, Abotsi J, Asiedu K, Wansbrough-Jones MH. A severe case of Buruli ulcer disease with pleural effusions. PLoS Negl Trop Dis. 2014 Jun;8(6):e2868.

Phillips RO, Frimpong M, Sarfo FS, Kretschmer B, Beissner M, Debrah A, Ampem-Amoako Y, Abass KM, Thompson W, Duah MS, Abotsi J, Adjei O, Fleischer B, Bretzel G, Wansbrough-Jones M, Jacobsen M. Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana. Emerg Infect Dis. 2014 Jun;20(6):1000-3.

Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis. 2014 Apr 15;14:202.

Sarfo FS, Sarfo MA, Norman B, Phillips R, Chadwick D. Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine’s epitaph?. PLoS One. 2014;9(4):e94854.

Phillips RO, Sarfo FS, Landier J, Oldenburg R, Frimpong M, Wansbrough-Jones M, Abass K, Thompson W, Forson M, Fontanet A, Niang F, Demangel C. Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease. PLoS Negl Trop Dis. 2014 Apr;8(4):e2786.

Jansson M, Beissner M, Phillips RO, Badziklou K, Piten E, Maman I, Sarfo FS, Huber KL, Rhomberg A, Symank D, Wagner M, Wiedemann F, Nitschke J, Banla Kere A, Herbinger KH, Adjei O, Löscher T, Bretzel G. Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease. J Clin Microbiol. 2014 Apr;52(4):1246-9.

Klis S, van der Werf TS, Phillips RO, Sarfo FS, Wansbrough-Jones M, Stienstra Y. Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice. AIDS. 2014 Mar 13;28(5):797-8.

Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, van der Werf TS. Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis. 2014 Mar;8(3):e2739.

Kollie K, Amoako YA, Ake J, Mulbah T, Zaizay F, Abass M, Lehman L, Paintsil A, Sarfo F, Lugala C, Tiendrebeogo A, Phillips R, Asiedu K. Buruli ulcer in Liberia, 2012. Emerg Infect Dis. 2014 Mar;20(3):494-6.

Williamson H, Phillips R, Sarfo S, Wansbrough-Jones M, Small P. Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana. PLoS One. 2014;9(2):e88007.

Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, Sarfo MA, Khoo S, Owen A, Chadwick DR. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother. 2014 Feb;69(2):491-9.

Vandelannoote K, Jordaens K, Bomans P, Leirs H, Durnez L, Affolabi D, Sopoh G, Aguiar J, Phanzu DM, Kibadi K, Eyangoh S, Manou LB, Phillips RO, Adjei O, Ablordey A, Rigouts L, Portaels F, Eddyani M, de Jong BC. Insertion sequence element single nucleotide polymorphism typing provides insights into the population structure and evolution of Mycobacterium ulcerans across Africa. Appl Environ Microbiol. 2014 Feb;80(3):1197-209.

Phillips RO, Sarfo FS, Abass MK, Abotsi J, Wilson T, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2014;58(2):1161-6.

Sarfo FS, Sarfo MA, Kasim A, Phillips R, Booth M, Chadwick D. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana. J Antimicrob Chemother. 2014 Jan;69(1):254-61.

Feldt T, Sarfo FS, Zoufaly A, Phillips RO, Burchard G, van Lunzen J, Jochum J, Chadwick D, Awasom C, Claussen L, Drosten C, Drexler JF, Eis-Hübinger AM. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. J Clin Virol. 2013 Sep;58(1):18-23.

Sarfo FS, Keegan R, Appiah L, Shakoor S, Phillips R, Norman B, Hardy Y, Bedu-Addo G, Longstaff L, Chadwick DR. High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians. J Infect. 2013 Jul;67(1):43-50.

Chadwick D, Stanley A, Sarfo S, Appiah L, Ankcorn M, Foster G, Schwab U, Phillips R, Geretti AM. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS. 2013 Jan 2;27(1):139-41..

Chadwick D, Ankcorn M, Sarfo F, Phillips R, Fox Z, Garcia A, Appiah L, Bedu-Addo G, Geretti AM. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother. 2012 Dec;67(12):2939-42.

Mamoojee Y, Tan G, Gittins S, Sarfo S, Stephenson L, Carrington D, Bedu-Addo G, Phillips R, Appiah LT, Chadwick D. Diagnosis of treponemal co-infection in HIV-infected West Africans. Trop Med Int Health. 2012 Dec;17(12):1521-6.

Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng NY, Sarfo FS, Jansson M, Huber KL, Herbinger KH, Battke F, Löscher T, Adjei O, Bretzel G. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. PLoS Negl Trop Dis. 2012;6(8):e1756.

Kariuki T, Phillips R, Njenga S, Olesen OF, Klatser PR, Porro R, Lock S, Cabral MH, Gliber M, Hanne D. Research and capacity building for control of neglected tropical diseases: the need for a different approach. PLoS Negl Trop Dis. 2011;5(5):e1020.

Bates I, Phillips R, Martin-Peprah R, Kibiki G, Gaye O, Phiri K, Tagbor H, Purnell S. Assessing and strengthening African universities’ capacity for doctoral programmes. PLoS Med. 2011 Sep;8(9):e1001068.

Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, Lenormand P, Dosso M, Wansbrough-Jones M, Veyron-Churlet R, Guenin-Macé L, Demangel C. Mycolactone diffuses into the peripheral blood of Buruli ulcer patients–implications for diagnosis and disease monitoring. PLoS Negl Trop Dis. 2011 Jul;5(7):e1237

Sarfo FS, Lavender CJ, Fyfe JA, Johnson PD, Stinear TP, Phillips RO. Mycobacterium ulcerans DNA not detected in faecal samples from Buruli ulcer patients: results of a pilot study. PLoS One. 2011 May 4;6(5):e19611.

Mamoojee Y, Shakoor S, Gorton RL, Sarfo S, Appiah LT, Norman B, Balakrishnan I, Phillips R, Chadwick D. Short Communication: Low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Trop Med Int Health. 2011 Jan;16(1):53-6.

Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85.

Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M, Garcia A, Phillips RO. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010 Sep;48(9):3223-30.

Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, Asiedu KB, Small PL, Wansbrough-Jones MH. Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis. 2010 Jan 5;4(1):e577.

Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis. 2009 Dec 1;200(11):1675-84.

Sarfo FS, Bibby DF, Schwab U, Appiah LT, Clark DA, Collini P, Phillips R, Green I, Dittmar MT, Chadwick DR. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. J Antimicrob Chemother. 2009 Sep;64(3):667-9.

Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M, Portaels F. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol. 2009 May;198(2):69-77.

Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol. 2009 Apr;47(4):924-6.

Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol. 2009 Jan;16(1):61-5.

Wansbrough-Jones Mark and Phillips Richard. Buruli ulcer: emerging out of obscurity  2006 The Lancet; 367: 1849-58.

Cosgrove Catherine, Castello-Branco L, Hussel T, Sexton A, Giemza R, Phillips Richard, Williams A, Griffin George, Dougan G, Lewis David. Boosting of Cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG sub-strain Moreau Rio de Janeiro oral vaccine. 2006 Infection and Immunity 74 (4): 2449-2452.

Phillips R, Horsfield C, Mangan J, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Butcher P, Lucas S, Wansbrough-Jones M. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun. 2006 May;74(5):2917-24.

Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol. 2006 Feb;13(2):253-7..

Etuaful Samuel, Carbonnelle B, Grosset Jacque, Lucas Sebastian, Horsfield Catherine, Phillips Richard, Evans Mark, Ofori-Adjei David, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah Peter, Ampadu Edwin, Amofah George, Asiedu Kingsley, Wansbrough-Jones Mark.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.  Antimicrob Agents Chemother. 2005 Aug; 49(8): 3182-6.

Tjip S van der Werf, Ymkje Stienstra, R Christian Johnson, Richard Phillips, Ohene Adjei, Bernhard Fleischer, Mark H Wansbrough-Jones, Paul D R Johnson, Françoise Portaels, Winette T A van der Graaf, Kingsley Asiedu: Mycobacterium ulcerans disease. Bulletin of the World Health Organisation 11/2005; 83(10):785-91.

Wansbrough-Jones Mark, Phillips Richard. Buruli ulcer.  BMJ. 2005 Jun18; 330(7505): 1402-3.

Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol. 2005 Aug;43(8):3650-6..

Kerry SM, Emmett L, Micah FB, Martin-Peprah R, Antwi S, Phillips RO, Plange-Rhule J, Eastwood JB, Cappuccio FP. Rural and semi-urban differences in salt intake, and its dietary sources, in Ashanti, West Africa. Ethn Dis. 2005 Winter;15(1):33-9. PubMed PMID: 15720047.

Kerry SM, Emmett L, Micah FB, Martin-Peprah R, Antwi S, Phillips RO, Plange-Rhule J, Eastwood JB, Cappuccio FP. For the patient. How much salt is used in Ashanti, West Africa?. Ethn Dis. 2005 Winter;15(1):150-1. PubMed PMID: 15720062.

Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother. 2004 Aug;48(8):2866-70.

Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, Kolk AH. In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother. 2004 Aug;48(8):3130-2.

Cappuccio FP, Micah FB, Emmett L, Kerry SM, Antwi S, Martin-Peprah R, Phillips RO, Plange-Rhule J, Eastwood JB. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension. 2004 May;43(5):1017-22.

Thangaraj HS, Phillips RO, Evans MR, Wansbrough-Jones MH. Emerging aspects of Buruli ulcer. Expert Rev Anti Infect Ther. 2003 Aug;1(2):217-22.

Evans MR, Phillips R, Etuaful SN, Amofah G, Adomako J, Adjei O, Dennis-Antwi J, Lucas SB, Wansbrough-Jones MH. An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans R Soc Trop Med Hyg. 2003 Mar-Apr;97(2):159-60.

Cappuccio FP, Plange-Rhule J, Phillips RO, Eastwood JB. Prevention of hypertension and stroke in Africa. Lancet. 2000 Aug 19;356(9230):677-8.

Plange-Rhule J, Phillips R, Acheampong JW, Saggar-Malik AK, Cappuccio FP, Eastwood JB. Hypertension and renal failure in Kumasi, Ghana. J Hum Hypertens. 1999 Jan;13(1):37-40. PubMed PMID: 9928750.


  • European & Developing Countries Clinical Trials Partnership
  • WHO/ TDR, the Special Programme for Research andTraining in Tropical Diseases co sponsored by UNICEF, UNDP, the World Bank and WHO Impact Award 2015
  • UK Medical Research Council (MRC) and the UK Department for International Development (DFID)
  • German Research Foundation (DFG)
  • National Institute of Health Research (United Kingdom) and Innovation for Global Health

  • Liverpool School of Tropical Medicine (Sanofi)



Dr. Stephen Fred Sarfo (2014): “The microbiological, clinical, immunological and mycolactone response to antibiotic therapy for M. ulcerans disease in humans and in a mouse model"

Dr. Michael Frimpong (2015): “Cellular Immune response to Mycobacterium ulcerans infection”

Dr Daniel Antwi Berko (2017): “Analysis of the immune-modulatory effects of Mansonella perstans infection associated with concomitant Mycobacterium ulcerans disease and Tuberculosis infection in Ghana.”

Master of Philosophy

Mr. Hubert Ahor Senanu (2021): Rapid detection of Mycobaterium ulcerans using real time recombinase polymerase amplification (RPA) in the field.

Ms. Abigail Agbanyo (2020): The use of serological and molecular tools in the surveillance of Buruli ulcer and Yaws in southwestern part of Ghana

Ms. Nancy Ackam (2019): Assessment of microfilaricidal activity of combined administration of ivermectin and albendazole against onchocerciasis

Ms Francisca Naana Sarpong (2019): Proteomics of Buruli Ulcer Disease Healing

Mrs Mabel Sarpong-Duah (2016): “Detection of viability markers of Mycobacterium ulcerans and their association with healing in Buruli ulcer patients “

Mr. Aloysius D. Loglo (2016): “Analysis of the Vaccine Potential of Plasmid DNA Encoding Mycolactone Polyketide Synthase Domains in patients with M. ulcerans disease”

Ms. Benedette Agbavor (2016): Comparative detection of Mycobacterium ulcerans DNA by PCR from FTA cards, cell  solution and RNA protect solution

Ms Vera Opoku (2016): Molecular and epidemiological studies on disease and vector of Mansonella perstans